Ampio Wins Investigational Review Board Approval for Phase 1 Long Covid-19 Trial
11:07 AM EDT, 05/10/2021 (MT Newswires) -- Ampio Pharmaceuticals (AMPE) said Monday the Investigational Review Board has cleared the company's phase 1 trial of Ampion in patients exhibiting prolonged COVID-19 symptoms, known as "long-haulers," to start patient enrollment.
The trial, which is expected to enroll 30 patients, will evaluate the safety and efficacy of inhaled Ampion in adults with prolonged respiratory complications after COVID-19 infection as compared to placebo.
Shares were more than 1% lower in morning session.
Price: 1.82, Change: -0.03, Percent Change: -1.62